Dr Reddy’s shares jump 3% despite 36% profit fall; check what 7 brokerages recommend
Dr. Reddy's Laboratories' shares rose 3.18% to Rs 1,268.60 despite a 36% YoY profit decline to Rs 913.4 crore in Q2. Revenue fell 1.5% to Rs 8,671 crore. Brokerages offered mixed outlooks, with targets ranging from Rs 1,270 to Rs 1,730, citing margin performance and upcoming product developments.
How this was made
The 30-second read
Why it matters
Earnings miss and margin contraction create short‑term risk, while upgraded targets provide upside opportunities.
Market read
First‑report earnings data for a mid‑cap pharma company with mixed analyst sentiment, offering a modest trading opportunity.
What to watch
Potential upcoming US approvals for abatacept and semaglutide supply resumption could boost future earnings.
Background
The article details Dr Reddy's September quarter financials and summarizes analyst target revisions and upgrade actions.
Ticker impact
Dr Reddy's reported a 36% profit decline and 1.5% revenue drop for the September quarter, with margins contracting, prompting a 3% share rise on mixed analyst upgrades.
potential downside from profit miss, offset by upside from margin recovery and analyst upgrades
The profit fall is material, yet several brokerages raised targets, suggesting a near‑term trade range rather than a clear directional move.
Market effects
Indian pharmaceutical sector may see margin pressure as peers report similar cost challenges.
Indian equity markets could react to the earnings miss and analyst upgrades.
Limited impact outside emerging markets; US investors may watch ADR RDY for short‑term moves.
Counterpoint
Despite the profit decline, the stock's 3% rise suggests buying on dip could be justified if margin recovery accelerates.
Key entities
- companyDr Reddy's Laboratories
Indian pharmaceutical manufacturer reporting September quarter results.
- analystNomura
Maintained buy rating, slightly lowered target price.
